TransCode Therapeutics (RNAZ) Stock Price, News & Analysis

Company Overview

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $6.96 to $7.23
• 50-Day Range: $6.63 to $15.79
• 52-Week Range: $6.15 to $1,541.79
• Volume: 23,598 shs
• Average Volume: 101,452 shs
• Market Capitalization: $5.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $280.00
• Consensus Rating: Buy

TransCode Therapeutics Stock Analysis - MarketRank™

TransCode Therapeutics scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TransCode Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TransCode Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TransCode Therapeutics are expected to grow in the coming year, from ($4.76) to ($4.37) per share.

Price to Book Value per Share Ratio

TransCode Therapeutics has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.99% of the float of TransCode Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TransCode Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TransCode Therapeutics has recently decreased by 89.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TransCode Therapeutics does not currently pay a dividend.

Dividend Growth

TransCode Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.99% of the float of TransCode Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TransCode Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TransCode Therapeutics has recently decreased by 89.80%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.96

News Sentiment

TransCode Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for TransCode Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for RNAZ on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of TransCode Therapeutics is held by insiders.

RNAZ Stock Analysis - Frequently Asked Questions

How have RNAZ shares performed this year?

TransCode Therapeutics' stock was trading at $94.36 at the beginning of the year. Since then, RNAZ stock has decreased by 92.5% and is now trading at $7.03.
View the best growth stocks for 2025 here.

How were TransCode Therapeutics' earnings last quarter?

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) posted its earnings results on Wednesday, May, 21st. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($2.00) by $1.40.

When did TransCode Therapeutics' stock split?

Shares of TransCode Therapeutics reverse split on the morning of Tuesday, January 16th 2024. The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did TransCode Therapeutics IPO?

TransCode Therapeutics (RNAZ) raised $25 million in an IPO on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share.

Who are TransCode Therapeutics' major shareholders?

Top institutional investors of TransCode Therapeutics include Anson Funds Management LP (175.52%), Anson Funds Management LP (6.26%) and Warberg Asset Management LLC (0.21%). Insiders that own company stock include Robert Michael Dudley and Thomas A Fitzgerald.
View institutional ownership trends.

How do I buy shares of TransCode Therapeutics?

Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TransCode Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TransCode Therapeutics investors own include Mullen Automotive (MULN), Plug Power (PLUG), AMC Entertainment (AMC), Nuwellis (NUWE), ARMOUR Residential REIT (ARR), BIOLASE (BIOL) and Imperial Petroleum (IMPP).

Company Calendar

• Last Earnings: 5/21/2025
• Today: 6/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNAZ
• CIK: 1829635
• Web: www.transcodetherapeutics.com
• Phone: 857-837-3099
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $280.00
• High Stock Price Target: $280.00
• Low Stock Price Target: $280.00
• Potential Upside/Downside: +3,882.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.55 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -649.03%
• Return on Assets: -281.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.58
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $86.32 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 833,000
• Free Float: 677,000
• Market Cap: $5.86 million
• Optionable: Not Optionable
• Beta: 1.52